Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Study of Cenicriviroc in NASH
NCT03059446Phase 2Terminated
- Sponsor
- Tobira Therapeutics
- Start
- Feb 2017
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of cenicriviroc in Nonalcoholic steatohepatitis (NASH), Liver Fibrosis (LF), sponsored by Tobira Therapeutics. Started Feb 2017; status: terminated.
02
Drugs
cenicriviroc
03
Conditions
Nonalcoholic steatohepatitis (NASH)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT03059446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03059446.